From: Cystatin C and long term risk of community-acquired sepsis: a population-based cohort study
Variable | Unadjusted | Model 1 | Model 2 | Model 3 | Model 4 | Model 5 |
---|---|---|---|---|---|---|
Cystatin C ā„1.12 mg/dL | 2.70 (2.43-3.00) | 1.51 (1.32-1.72) | Ā | 1.60 (1.40-1.83) | Ā | Ā |
Cystatin C Quartiles | Ā | Ā | Ā | Ā | Ā | Ā |
Q1 (<0.83 mg/dL) | Ref | Ā | Ref | Ā | Ref | Ā |
Q2 (0.83-0.94 mg/dL) | 1.40 (1.16-1.69) | Ā | 1.14 (0.94-1.37) | Ā | 1.14 (0.94-1.38) | Ā |
Q3 (0.95-1.12 mg/dL) | 1.81 (1.51-2.17) | Ā | 1.20 (0.96-1.45) | Ā | 1.22 (1.01-1.47) | Ā |
Q4 (>1.12 mg/dL) | 3.77 (3.20-4.45) | Ā | 1.72 (1.42-2.09) | Ā | 1.85 (1.51-2.27) | Ā |
Cystatin C (per SD) (mg/dL) | 1.24 (1.21-1.27) | Ā | Ā | Ā | Ā | 1.16 (1.11-1.21) |
eGFR <60 ml/min/1.73m2 | 2.38 (2.10-2.70) | 1.14 (0.98-1.32) | 1.14 (0.98-1.32) | Ā | Ā | Ā |
ACR ā„30 mg/g | 2.22 (1.97-2.49) | 1.45 (1.28-1.65) | 1.45 (1.28-1.65) | Ā | Ā | Ā |
hsCRP >3.0 mg/dL | 1.71 (1.54-1.90) | 1.48 (1.32-1.65) | 1.47 (1.31-1.64) | Ā | Ā | Ā |
eGFR <73.1 ml/min/1.73m2 | 1.91 (1.72-2.12) | Ā | Ā | 1.00 (0.87-1.14) | 0.98 (0.86-1.12) | Ā |
ACR ā„16.1 mg/g | 2.05 (1.85-2.28) | Ā | Ā | 1.41 (1.26-1.58) | 1.41 (1.26-1.58) | Ā |
hsCRP >5.0 mg/dL | 1.75 (1.57-1.95) | Ā | Ā | 1.51 (1.34-1.69) | 1.49 (1.33-1.68) | Ā |
eGFR (per SD) (ml/min/1.73m2) | 0.69 (0.65-0.72) | Ā | Ā | Ā | Ā | 0.97 (0.90-1.04) |
ACR (per SD) (mg/g) | 1.07 (1.03-1.11) | Ā | Ā | Ā | Ā | 1.01 (0.97-1.06) |
hsCRP (per SD) (mg/dL) | 1.12 (1.10-1.15) | Ā | Ā | Ā | Ā | 1.10 (1.06-1.14) |